Device Neurology

Ceribell Rapid Response Eeg

Payments companies reported to CMS as associated with Ceribell Rapid Response Eeg. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.2Massociated payments (2023-2025)
395clinicians with associated payments
1company reporting

By year

2023 $1.2M

Payments reported as associated with Ceribell Rapid Response Eeg, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $569K
Emergency Medicine $212K
Epilepsy $106K
Critical Care Medicine (Internal Medicine) $64K
Neurology With Special Qualifications In Child Neurology $60K
Psychiatry $59K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ceribell Rapid Response Eeg

These are the largest totals companies reported as associated with Ceribell Rapid Response Eeg. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Parshaw Dorriz Mission Viejo, CA Neurology (Psychiatry & Neurology) $349,038.04
Matthew Kaplan Mission Viejo, CA Emergency Medicine $123,184.71
Kapil Gururangan Chicago, IL Epilepsy $92,448.22
Jacob Adams Sacramento, CA Psychiatry $59,191.78
John Stern Los Angeles, CA Neurology (Psychiatry & Neurology) $48,670.53
John Rickelman Quincy, IL Critical Care Medicine (Internal Medicine) $44,781.57
Richard Kozak Mission Viejo, CA Emergency Medicine $41,600.40
Susan Levy Guilford, CT Neurology With Special Qualifications In Child Neurology $37,800.00
Khalid Alsherbini Memphis, TN Neurology (Psychiatry & Neurology) $32,515.31
Matthew Markert Santa Cruz, CA Neurology (Psychiatry & Neurology) $23,259.50

Prescribed Ceribell Rapid Response Eeg?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.